Various studies have identified the elevated presence of circulating PTX3 in patients with NAFLD, as compared to controls (51–53), in NASH patients as compared to patients with simple steatosis (51, 54) and in correlation with the severity of hepatic fibrosis (51, 54, 55). Here, PTX3 is linked to metabolic dysfunction-associated steatohepatitis.